-
2 weeks ago | 
ajmc.com | Giuliana Grossi |Christian C. Ruff |John B. Buse |Marc P. Bonaca |Marc Humbert |Jawad Haider Butt | +1 more
At the American College of Cardiology Annual Scientific Session (ACC.25), experts shared groundbreaking research poised to reshape cardiovascular care—particularly for women and patients with complex cardiometabolic conditions.
-
3 weeks ago | 
ajmc.com | Giuliana Grossi |Marc Humbert
In the phase 3 ZENITH trial, sotatercept (Winrevair; Merck) significantly reduced the risk of death, lung transplantation, or prolonged hospitalization due to worsening pulmonary arterial hypertension (PAH) compared with placebo.
-
3 weeks ago | 
pharmacytimes.com | Alexandra Gerlach |Marc Humbert
Author(s):,Marc Humbert, MD, PhD, shared data that were presented at the ACC 2025 Scientific Sessions. At the ACC 2025 Scientific Session, Marc Humbert, MD, professor of respiratory medicine at the South Paris University, discussed the role of sotatercept, a novel biologic therapy, in treating pulmonary arterial hypertension (PAH), particularly for patients at high risk of death.
-
Dec 6, 2024 | 
blogs.mediapart.fr | Marc Humbert
Lors de la pénurie de masques pour la Covid ou quand Michelin supprime des emplois, nombre d’entre nous rêvons de restaurer notre souveraineté industrielle c’est-à-dire d’abandonner la mondialisation. Mais son abandon nous inquiète s’il procède de la menace protectionniste de Trump. La mondialisation de l’économie, de quoi s’agit-il ? L’INSEE l’explique en indiquant que la France exportait ou importait 14 % de son PIB en 1965, et que c’est aujourd’hui 35 %.
-
Nov 27, 2024 | 
publications.ersnet.org | Gábor Kovács |Marc Humbert |Hôpital Bicêtre |Le Kremlin-Bicêtre
Original Research Article Prognostic relevance of Exercise Pulmonary Hypertension: Results of the multi-center PEX-NET Clinical Research Collaboration ArticleInfo & Metrics This is a PDF-only article. Please click on the PDF link above to read it.
-
Nov 14, 2024 | 
publications.ersnet.org | Marc Humbert |Faculté de Médecine |Le Kremlin-Bicêtre |Paul M Hassoun
IntroductionPulmonary arterial hypertension (PAH) is a debilitating, progressive disease marked by the remodelling and narrowing of the pulmonary vasculature [1–4].
-
Aug 5, 2024 | 
erj.ersjournals.com | Marc Humbert |Roberto Badagliacca |Andrew Coats |George Giannakoulas
According to the revised haemodynamic definition, PAH may be diagnosed in patients with mPAP >20 mmHg and PVR >2 WU. Yet, the efficacy of drugs approved for PAH has only been demonstrated in patients with mPAP ≥25 mmHg and PVR >3 WU (see , ). No data are available for the efficacy of drugs approved for PAH in patients whose mPAP is <25 mmHg and whose PVR is <3 WU. Hence, for such patients, the efficacy of drugs approved for PAH has not been established.
-
Jul 3, 2024 | 
blogs.mediapart.fr | Marc Humbert
Peut-on éviter que le pire soit encore à venir La dissolution a précipité tous les Français dans un maelström angoissant. N’y échappent que ceux prêts à s’afficher comme la force politique principale du pays. Ils occuperont plus de 250 sièges à l’Assemblée nationale quand ils n’en avaient pas 90. La question suivante est celle de savoir si notre pays saura se doter d’un gouvernement qui puisse obtenir un vote de confiance à l’assemblée.
-
Jun 6, 2024 | 
erj.ersjournals.com | Marc Humbert
FootnotesConflict of interest: M.
-
Nov 2, 2023 | 
erj.ersjournals.com | Marc Humbert
Pulmonary vascular remodelling and dysfunction are hallmarks of pulmonary arterial hypertension (PAH), a rare and severe form of pre-capillary pulmonary hypertension, causing shortness of breath, fatigue, chest pain, exercise limitation, altered quality of life and markedly reduced life expectancy, despite guideline-supported management with approved medications [1–5].
